<DOC>
	<DOC>NCT00776425</DOC>
	<brief_summary>This 2 arm study will investigate Quality of Life response in anemic patients with solid and lymphoid malignancies, who are receiving concomitant chemotherapy. Patients in treatment Arm 1 with solid and lymphoid malignancies will receive NeoRecormon at a dose of 150 IU/kg three times weekly. Patients in treatment Arm 2 with lymphoid malignancies will receive NeoRecormon 30,000 IU s.c. once weekly. The anticipated time on study treatment is up to 1 year, and the target sample size is 100-500 individuals.</brief_summary>
	<brief_title>A Study of the Quality of Life and Treatment Response to Once Weekly NeoRecormon (Epoetin Beta) Treatment in Anemic Patients With Solid and Lymphoid Malignancies.</brief_title>
	<detailed_description />
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>male and female patients; &gt;=18 years of age; anemia and prescribed treatment with NeoRecormon; confirmed diagnosis of a solid or lymphoid hematologic malignancy; receiving or scheduled to receive chemotherapy; life expectancy of &gt;=6 months. anemia after bleeding, hemolytic anemia, megaloblastic anemia, anemia in chronic kidney failure, lever and endocrinology diseases; contraindications to NeoRecormon; administration of NeoRecormon during chemotherapy (e.g. on the third day after chemotherapy cycle start); bleeding within one month before and/or during study; severe infection within one month before and/or during study; inability of patient to fill the questionnaires in.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>